Juan Arenas
University of the Basque Country
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Juan Arenas.
The New England Journal of Medicine | 2012
Enrique Quintero; Antoni Castells; Luis Bujanda; Joaquín Cubiella; Dolores Salas; Angel Lanas; Montserrat Andreu; Fernando Carballo; Juan Diego Morillas; Cristina Hernández; Rodrigo Jover; Isabel Montalvo; Juan Arenas; Eva Laredo; Vicent Hernandez; Felipe Iglesias; Estela Cid; Raquel Zubizarreta; Teresa Sala; Marta Ponce; Mercedes Andrés; Gloria Teruel; Antonio Peris; María-Pilar Roncales; Mónica Polo-Tomás; Xavier Bessa; Olga Ferrer-Armengou; Jaume Grau; Anna Serradesanferm; Akiko Ono
BACKGROUND Colonoscopy and fecal immunochemical testing (FIT) are accepted strategies for colorectal-cancer screening in the average-risk population. METHODS In this randomized, controlled trial involving asymptomatic adults 50 to 69 years of age, we compared one-time colonoscopy in 26,703 subjects with FIT every 2 years in 26,599 subjects. The primary outcome was the rate of death from colorectal cancer at 10 years. This interim report describes rates of participation, diagnostic findings, and occurrence of major complications at completion of the baseline screening. Study outcomes were analyzed in both intention-to-screen and as-screened populations. RESULTS The rate of participation was higher in the FIT group than in the colonoscopy group (34.2% vs. 24.6%, P<0.001). Colorectal cancer was found in 30 subjects (0.1%) in the colonoscopy group and 33 subjects (0.1%) in the FIT group (odds ratio, 0.99; 95% confidence interval [CI], 0.61 to 1.64; P=0.99). Advanced adenomas were detected in 514 subjects (1.9%) in the colonoscopy group and 231 subjects (0.9%) in the FIT group (odds ratio, 2.30; 95% CI, 1.97 to 2.69; P<0.001), and nonadvanced adenomas were detected in 1109 subjects (4.2%) in the colonoscopy group and 119 subjects (0.4%) in the FIT group (odds ratio, 9.80; 95% CI, 8.10 to 11.85; P<0.001). CONCLUSIONS Subjects in the FIT group were more likely to participate in screening than were those in the colonoscopy group. On the baseline screening examination, the numbers of subjects in whom colorectal cancer was detected were similar in the two study groups, but more adenomas were identified in the colonoscopy group. (Funded by Instituto de Salud Carlos III and others; ClinicalTrials.gov number, NCT00906997.).
BMC Gastroenterology | 2008
Luis Bujanda; Elizabeth Hijona; Mikel Larzabal; Marta Beraza; P. Aldazabal; Nerea García-Urkia; Cristina Sarasqueta; Angel Cosme; Belen Irastorza; Alberto Bradshaw Gonzalez; Juan Arenas
BackgroundThe prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic steatosis in an animal model of steatosis, and whether this therapeutic approach resulted in a decrease in tumor necrosis factor α (TNF-α) production, lipid peroxidation and oxidative stress.MethodsMale Wistar CRL: Wi (Han) (225 g) rats were randomized into three groups. A control group (n = 12) was given free access to regular dry rat chow for 4 weeks. The steatosis (n = 12) and resveratrol (n = 12) groups were given free access to feed (a high carbohydrate-fat free modified diet) and water 4 days per week, and fasted for the remaining 3 days for 4 weeks. Rats in the resveratrol group were given resveratrol 10 mg daily by the oral route. All rats were killed at 4 weeks and assessed for fatty infiltration and bacterial translocation. Levels of TNF-α in serum, hepatic malondialdehyde (MDA), oxidative stress (superoxide dismutase, glutathione peroxidase, catalase and nitric oxide synthase) and biochemical parameters were measured.ResultsFat deposition was decreased in the resveratrol group as compared to the steatosis group (Grade 1 vs Grade 3, P < 0.05). TNF-α and MDA levels were significantly increased in the steatosis group (TNF-α; 33.4 ± 5.2 vs 26.24 ± 3.47 pg/ml and MDA; 9.08 ± 0.8 vs 3.17 ± 1.45 μM respectively, P < 0.05). This was accompanied by increased superoxide dismutase, glutathione peroxidase and catalase and decreased nitric oxide synthase in the liver of resveratrol group significantly (P < 0.05 vs steatosis group). Bacterial translocation was not found in any of the groups. Glucose levels were decreased in the group of rats given resveratrol (P < 0.05).ConclusionResveratrol decreased NAFLD severity in rats. This effect was mediated, at least in part, by TNF-α inhibition and antioxidant activities.
Mediators of Inflammation | 2010
Elizabeth Hijona; Lander Hijona; Juan Arenas; Luis Bujanda
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming a world-wide public health problem. NAFLD represents a spectrum of disease ranging from “simple steatosis”, which is considered relatively benign, to nonalcoholic steatohepatitis and to NAFLD-associated cirrhosis and end-stage liver disease. The etiology of NAFLD and its progression is complex and remains incompletely understood. The progression of the disease involves many factors. Apart from the two hits, the accumulation of TG and the development of fibrosis and necroinflammatory processes, exit numerous molecules associated with these two hits. Among them we can highlight the pro-inflammatory molecules and adiponectins. This review focuses on the growing evidence from both experimental and human studies suggesting a central role of cytokines in the pathogenesis of NAFLD. We review the role of cytokines as key regulators of insulin sensitivity and hepatic lipid overloading, liver injury and inflammation, and fibrosis with an emphasis on potential therapeutic implications.
Helicobacter | 2004
Ma Teresa Arroyo; Montse Forne; Carlos Martín de Argila; Faust Feu; Juan Arenas; Juan de la Vega; Vicente Garrigues; Francisco Mora; Manuel Castro; Luis Bujanda; Angel Cosme; Agustin Castiella; Javier P. Gisbert; Antonio Hervás; Angel Lanas
Background and Aim. Helicobacter pylori is the major cause of peptic ulcer disease, but the proportion of H. pylori‐negative peptic ulcers seems to be increasing in developed countries. We investigated the frequency of H. pylori‐negative peptic ulcer without intake of nonsteroidal anti‐inflammatory drugs (NSAIDs) in a Mediterranean European country.
Gut | 2007
Luis Bujanda; Cristina Sarasqueta; Leire Zubiaurre; Angel Cosme; Carmen Muñoz; Araceli Sánchez; Cristina Martín; Llúcia Titó; Virginia Piñol; Antoni Castells; Xavier Llor; Rosa M. Xicola; Elisenda Pons; Juan Clofent; Maria Dolores Luque de Castro; Jaime Cuquerella; Enrique Medina; Ana Gutiérrez; Juan Arenas; Rodrigo Jover
Background: Colonoscopy is one of the methods of choice for screening relatives of patients with colorectal cancer. Objective: To evaluate the rate of adherence to colonoscopy in first-degree relatives of patients with colorectal cancer and describe the lesions found. Methods: A prospective, cross-sectional, multicentre, nationwide study was conducted. The study population was composed of first-degree relatives of patients with colorectal cancer selected randomly from the EPICOLON study. Seventy-four index patients were included. These had 342 living first-degree relatives (parents, siblings and children), of whom 281 were interviewed. Results: The adherence rate was 38% (107/281). Adherence was greater in families with a higher degree of familial aggregation for colorectal cancer (88.9% for Amsterdam vs 33.3% for Bethesda and sporadic cancer; p<0.05), an index patient aged under 65 years (60% for patients <65 years vs 32.9% for patients ⩾65 years; p<0.05) and an index patient who was female (46.2% for women vs 31% for men; p = 0.28). Adherence was also greater in relatives under 65 years (54% in patients <65 years vs 18% in patients ⩾65 years; p = 0.05), in female relatives (49% in female relatives vs 27.3% in male relatives; p<0.05) and in siblings and children (40% in siblings and children vs 13% in parents; p<0.05). Lesions were found in 26% (28/107) of the study population. Nine (8.4%) individuals had a total of 18 advanced lesions. Conclusions: These results indicate that adherence to colonoscopy in our population of first-degree relatives was low. The adherence was more frequently associated with a higher degree of familial aggregation, a relative age of under 65 years, a sibling or offspring relationship, and female sex.
Gastrointestinal Endoscopy | 2013
Rodrigo Jover; Pedro Zapater; Eduardo Polanía; Luis Bujanda; Angel Lanas; Jose Antonio Hermo; Joaquín Cubiella; Akiko Ono; Yanira González-Méndez; Antonio Peris; Maria Pellise; Agustín Seoane; Alberto Herreros-de-Tejada; Marta Ponce; Jc Marín-Gabriel; María Chaparro; Guillermo Cacho; Servando Fernández-Díez; Juan Arenas; Federico Sopeña; Luisa De-Castro; Pablo Vega-Villaamil; Maria Rodriguez-Soler; Fernando Carballo; Dolores Salas; Juan Diego Morillas; Montserrat Andreu; Enrique Quintero; Antoni Castells
BACKGROUND Adenoma detection rate (ADR) has become the most important quality indicator for colonoscopy. OBJECTIVE The aim of this study was to investigate which modifiable factors, directly related to the endoscopic procedure, influenced the ADR in screening colonoscopies. DESIGN Observational, nested study. SETTING Multicenter, randomized, controlled trials. PATIENTS Asymptomatic people aged 50 to 69 years were eligible for a multicenter, randomized, controlled trial designed to compare colonoscopy and fecal immunochemical testing in colorectal cancer screening. A total of 4539 individuals undergoing a direct screening colonoscopy were included in this study. INTERVENTION Colonoscopy. MAIN OUTCOME MEASUREMENTS Bowel cleansing, sedation, withdrawal time in normal colonoscopies, and cecal intubation were analyzed as possible predictors of adenoma detection by using logistic regression analysis, adjusted for age and sex. RESULTS In multivariate analysis, after adjustment for age and sex, factors independently related to the ADR were a mean withdrawal time longer than 8 minutes (odds ratio [OR] 1.51; 95% CI, 1.17-1.96) in normal colonoscopies and split preparation (OR 1.26; 95% CI, 1.01-1.57). For advanced adenomas, only withdrawal time maintained statistical significance in the multivariate analysis. For proximal adenomas, withdrawal time and cecal intubation maintained independent statistical significance, whereas only withdrawal time longer than 8 minutes and a <10-hour period between the end of preparation and colonoscopy showed independent associations for distal adenomas. LIMITATIONS Only endoscopic variables have been analyzed. CONCLUSION Withdrawal time was the only modifiable factor related to the ADR in colorectal cancer screening colonoscopies associated with an increased detection rate of overall, advanced, proximal, and distal adenomas.
BMC Gastroenterology | 2006
Luis Bujanda; María García-Barcina; Virginia Gutiérrez-de Juan; Joseba Bidaurrazaga; Marian Fernández de Luco; Marian Gutiérrez-Stampa; Mikel Larzabal; Elisabeth Hijona; Cristina Sarasqueta; Miguel Echenique-Elizondo; Juan Arenas
BackgroundResveratrol is a polyphenol with important antiinflammatory and antioxidant properties. We investigated the effect of resveratrol on alcohol-induced mortality and liver lesions in mice.MethodsMice were randomly distributed into four groups (control, resveratrol-treated control, alcohol and resveratrol-treated alcohol). Chronic alcohol intoxication was induced by progressively administering alcohol in drinking water up to 40% v/v. The mice administered resveratrol received 10 mg/ml in drinking water. The animals had free access to standard diet. Blood levels were determined for transaminases, IL-1 and TNF-α. A histological evaluation was made of liver damage, and survival among the animals was recorded.ResultsTransaminase concentration was significantly higher in the alcohol group than in the rest of the groups (p < 0.05). IL-1 levels were significantly reduced in the alcohol plus resveratrol group compared with the alcohol group (p < 0.05). TNF-α was not detected in any group. Histologically, the liver lesions were more severe in the alcohol group, though no significant differences between groups were observed. Mortality in the alcohol group was 78% in the seventh week, versus 22% in the alcohol plus resveratrol group (p < 0.001). All mice in the alcohol group died before the ninth week.ConclusionThe results obtained suggest that resveratrol reduces mortality and liver damage in mice.
Journal of Hepatology | 2017
Jose Luis Calleja; Javier Crespo; Diego Rincón; Belén Ruiz-Antorán; Inmaculada Fernández; C. Perelló; F. Gea; Sabela Lens; J. García-Samaniego; B. Sacristan; María García-Eliz; S. Llerena; J.M. Pascasio; Juan Turnes; X. Torras; Rosa Maria Morillas; Jordi Llaneras; Miguel A. Serra; M. Diago; Conrado Fernández Rodriguez; Javier Ampuero; F. Jorquera; Miguel A. Simón; Juan Arenas; C.A. Navascués; Rafael Bañares; Raquel Muñoz; Agustín Albillos; Zoe Mariño
BACKGROUND & AIMS Clinical trials evaluating second-generation direct-acting antiviral agents (DAAs) have shown excellent rates of sustained virologic response (SVR) and good safety profiles in patients with chronic hepatitis C virus (HCV) genotype 1 infection. We aimed to investigate the effectiveness and safety of two oral DAA combination regimens, ombitasvir/paritaprevir/ritonavir plus dasabuvir (OMV/PTV/r+DSV) and ledipasvir/sofosbuvir (LDV/SOF), in a real-world clinical practice. METHODS Data from HCV genotype 1 patients treated with either OMV/PTV/r+DSV±ribavirin (RBV) (n=1567) or LDV/SOF±RBV (n=1758) in 35 centers across Spain between April 1, 2015 and February 28, 2016 were recorded in a large national database. Demographic, clinical and virological data were analyzed. Details of serious adverse events (SAEs) were recorded. RESULTS The two cohorts were not matched with respect to baseline characteristics and could not be compared directly. The SVR12 rate was 96.8% with OMV/PTVr/DSV±RBV and 95.8% with LDV/SOF±RBV. No significant differences were observed in SVR according to HCV subgenotype (p=0.321 [OMV/PTV/r+DSV±RBV] and p=0.174 [LDV/SOF]) or degree of fibrosis (c0.548 [OMV/PTV/r/DSV±RBV] and p=0.085 [LDV/SOF]). Only baseline albumin level was significantly associated with failure to achieve SVR (p<0.05) on multivariate analysis. Rates of SAEs and SAE-associated treatment discontinuation were 5.4% and 1.7%, in the OMV/PTV/r+DSV subcohort and 5.5% and 1.5% in the LDV/SOF subcohort, respectively. Hepatocellular carcinoma (HCC) recurred in 30% of patients with a complete response to therapy for previous HCC. Incident HCC was reported in 0.93%. CONCLUSIONS In this large cohort of patients managed in the real-world setting in Spain, OMV/PTV/r+DSV and LDV/SOF achieved high rates of SVR12, comparable to those observed in randomized controlled trials, with similarly good safety profiles. LAY SUMMARY In clinical trials, second-generation direct-acting antiviral agents (DAAs) have been shown to cure over 90% of patients chronically infected with the genotype 1 hepatitis C virus and have been better tolerated than previous treatment regimens. However, patients enrolled in clinical trials do not reflect the real patient population encountered in routine practice. The current study, which includes almost 4,000 patients, demonstrates comparable rates of cure with two increasingly used DAA combinations as those observed in the clinical trial environment, confirming that clinical trial findings with DAAs translate into the real-world setting, where patient populations are more diverse and complex.
The American Journal of Gastroenterology | 1998
Jose M Marimón; Luis Bujanda; María A Gutiérrez-Stampa; Angel Cosme; Juan Arenas
pattern of clinical recognition. J Clin Gastroenterol 1988;10:395–400. 4. Perelman S, Dupuy C, Bourillon A. The association of pulmonary hemosiderosis and celiac disease: A propos of a new case in a child. Ann Pediatr 1992;39:185–8. 5. Pacheco A, Casanova C, Fogue L, et al. Long-term clinical follow-up of adult idiopathic pulmonary hemosiderosis and celiac disease. Chest 1991;99:1525–6. 6. Chagnon A, Carli P, de Jaureguiberry JP, et al. Cardiomyopathy associated with celiac disease. Presse Med 1990;19:1415–6. 7. Cano A, Barbado FJ, Matı ́n MA, et al. Tetania como forma de presentacio ́n de la enfermedad celiaca del adulto. Ann Med Intern 1996; 13:592–4. 8. McIntire AS, Long RG. Prospective survey of investigations in outpatients referred with iron deficiency anemia. Gut 1993;34:1102–7. 9. Gaum WE, Aterman K. Complete left bundle branch block in idiopathic pulmonary hemosiderosis. J Pediatr 1974;85:633–8. 10. Moses HW, Schereiner BF Jr, Hyde RW, et al. Heart block and idiopathic pulmonary hemosiderosis. PACE 1982;5:826–8. 11. Mah MW, Priel IE, Humen DP, et al. Idiopathic pulmonary hemosiderosis, complete heart block and celiac disease. Can J Cardiol 1989;5:191–4. 12. Corazza GR, Frisoti M, Filipponi C, et al. Investigation of QT interval in coeliac disease. BMJ 1992;304:1185.
Cancer | 1990
Julio Torrado; Eduardo Blasco; Ariel Gutierrez-Hoyos; Angel Cosme; Maria Lojendio; Juan Arenas
Alterations in the expression of type 1 blood group‐related antigens (Lewis a and b) were examined immunohistochemically in 371 consecutives gastric biopsy and 80 surgical specimens from patients of gastric carcinoma. The ABH and Lewis phenotype and secretor status of the patients were correlated with histologic findings. An anomalous expression of Lewis a antigen was found in 88 of 249 gastric biopsy specimens of Lewis (a–b+) phenotype patients. The prevalence of this anomaly increased with the evolution of the premalignant process, in agreement with the commonly accepted model of gastric carcinogenesis. Thus, anomalous Lewis a antigen appeared in 66.6% of gastric dysplasia cases, in 64.6% of intestinal metaplasia, in 15.4% of atrophic gastritis, and in 7.4% of superficial gastritis. No alterations were found in subjects with normal gastric mucosa. Forty‐seven of the 49 Lewis (a–b+) phenotype gastric carcinoma patients showed antigenic alterations in tumor cells (anomalous Lewis a antigen in 36 and loss of Lewis antigens in 11). In 26 of these gastric specimens an anomalous Lewis a antigen was present in areas of intestinal metaplasia and/or dysplasia away from the area of neoplastic transformation. The expression of Lewis a antigen in Lewis (a–b+) phenotype patients is a frequent phenomenon in gastric neoplastic cells and could result from the blocked synthesis of Lewis b antigen with accumulation of its precursors. These findings suggest that, during gastric carcinogenesis, antigenic alterations may precede neoplastic transformation. An anomalous Lewis a antigen could constitute a significant index of severity of the histologic lesion and contribute to identifying high‐risk individuals.